Mineralys Therapeutics Net Income Over Time
| MLYS Stock | 30.87 0.02 0.06% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mineralys Therapeutics Performance and Mineralys Therapeutics Correlation. Mineralys | Build AI portfolio with Mineralys Stock |
Is there potential for Biotechnology market expansion? Will Mineralys introduce new products? Factors like these will boost the valuation of Mineralys Therapeutics. Expected growth trajectory for Mineralys significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Mineralys Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mineralys Therapeutics is measured differently than its book value, which is the value of Mineralys that is recorded on the company's balance sheet. Investors also form their own opinion of Mineralys Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mineralys Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Mineralys Therapeutics' market value can be influenced by many factors that don't directly affect Mineralys Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Mineralys Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mineralys Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Mineralys Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Mineralys Therapeutics and related stocks such as Cidara Therapeutics, Scholar Rock Holding, and Ideaya Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDTX | (792 K) | (792 K) | (792 K) | (1.3 M) | (11.9 M) | (32.2 M) | (48.2 M) | (55.7 M) | (59 M) | (41.1 M) | (72.1 M) | (43.9 M) | (29.8 M) | (22.9 M) | (169.8 M) | (152.8 M) | (145.2 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (38.4 M) | (32.3 M) | (47.5 M) | (54.8 M) | (113 M) | (274.5 M) | (247 M) | (234.7 M) |
| ADPT | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (46.4 M) | (68.6 M) | (146.2 M) | (207.3 M) | (200.2 M) | (225.2 M) | (159.5 M) | (143.5 M) | (150.7 M) |
| BEAM | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (115.3 M) | (78.3 M) | (194.6 M) | (370.6 M) | (289.1 M) | (132.5 M) | (376.7 M) | (339.1 M) | (322.1 M) |
| CPRX | (255.9 K) | (6.4 M) | (4.1 M) | (12.2 M) | (15.5 M) | (20.2 M) | (18.1 M) | (18.4 M) | (34 M) | 31.9 M | 75 M | 39.5 M | 83.1 M | 71.4 M | 163.9 M | 188.5 M | 197.9 M |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (183.4 M) | (268.9 M) | (704.5 M) | (443.3 M) | (334.6 M) | (257.1 M) | (231.4 M) | (243 M) |
| APLS | (4 M) | (4 M) | (4 M) | (4 M) | (10.8 M) | (46.5 M) | (27.1 M) | (51 M) | (127.5 M) | (304.7 M) | (344.9 M) | (746.4 M) | (652.2 M) | (528.6 M) | (197.9 M) | (178.1 M) | (187 M) |
| AGIO | (23.7 M) | (23.7 M) | (20.1 M) | (39.4 M) | (53.5 M) | (117.7 M) | (198.5 M) | (314.7 M) | (346 M) | (411.5 M) | (327.4 M) | 1.6 B | (231.8 M) | (352.1 M) | 673.7 M | 774.8 M | 813.5 M |
| RXRX | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (87 M) | (178.1 M) | (239.4 M) | (328.1 M) | (463.7 M) | (417.3 M) | (396.4 M) |
Mineralys Therapeutics and related stocks such as Cidara Therapeutics, Scholar Rock Holding, and Ideaya Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Mineralys Therapeutics financial statement analysis. It represents the amount of money remaining after all of Mineralys Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Mineralys Therapeutics Common | MLYS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 150 N Radnor |
| Exchange | NASDAQ Exchange |
null 30.87
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics' price analysis, check to measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.